Valneva (NASDAQ:VALN) Shares Gap Up to $7.18

Valneva SE (NASDAQ:VALN)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $7.18, but opened at $7.48. Valneva shares last traded at $7.48, with a volume of 3,236 shares traded.

Analysts Set New Price Targets

VALN has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Valneva in a research report on Friday, May 31st. Guggenheim decreased their price target on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 22nd.

Valneva Price Performance

The company has a debt-to-equity ratio of 0.84, a current ratio of 2.64 and a quick ratio of 2.22. The business’s 50-day moving average price is $8.01 and its two-hundred day moving average price is $8.40. The firm has a market cap of $510.45 million, a price-to-earnings ratio of -18.24 and a beta of 2.28.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.12. The company had revenue of $35.56 million during the quarter, compared to analyst estimates of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. On average, research analysts forecast that Valneva SE will post -0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. lifted its holdings in shares of Valneva SE (NASDAQ:VALN) by 2.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the period. General American Investors Co. Inc. owned 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.